IDEC-C2B8 antibody data

IDPH presented positive data at the National Cancer Institute-EORTC Symposium on New Drugs and Cancer Therapy in Amsterdam. The data were from an ongoing Phase II combination trial with chemotherapy, and a follow-up report on a completed Phase II trial with of IDEC-C2B8 used as a single agent.

In the combination trial, all 29 patients treated to date have responded, and 28 responses are ongoing from 6 to 22 months. A complete response has been seen in 19 patients (66 percent), and 10 (34 percent) have had a partial response. Of 7 patients who expressed bcl-2, a cellular marker associated with malignant cells, prior to treatment, 6 became negative for that marker by the completion of therapy. ...